The expressions of SNORD16, SNORA73B, SCARNA4, and SNORD49B successfully discriminated BC patients from healthy volunteers (Fig. 3B-E), possessing AUCs of 0.7334 (Fig. 3B) with 76.75% sensitivity and 61.09% specificity, 0.7165 (Fig. 3C) with 68.38% sensitivity and 67.8% specificity, 0.6880 (Fig. 3D) with 58.37% sensitivity and 74.22% specificity, and 0.6728 (Fig. 3E) with 57.39% sensitivity and 70.22% specificity, respectively. This evidence concerns the gene SNORD16 and breast cancer.